KRAS Q61H
|
HCC
|
KRAS Q61H
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS Q61H
|
CRC
|
KRAS Q61H
|
CRC
|
trametinib + panitumumab Resistant: C3 – Early Trials
|
trametinib + panitumumab Resistant: C3 – Early Trials
|
KRAS Q61H
|
Sarcoma
|
KRAS Q61H
|
Sarcoma
|
trametinib Sensitive: C4 – Case Studies
|
trametinib Sensitive: C4 – Case Studies
|
KRAS Q61H
|
CRC
|
KRAS Q61H
|
CRC
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
KRAS Q61H
|
NSCLC
|
KRAS Q61H
|
NSCLC
|
P1446A-05 Sensitive: D – Preclinical
|
P1446A-05 Sensitive: D – Preclinical
|